SANUWAVE Health Reports Q2 2026 Revenue Decline and Net Loss

SANUWAVE Health, Inc. reported its financial results for the second quarter of 2026, revealing a revenue of $9.7 million, a decrease of approximately 3% from $10.1 million in the same period of 2025. For the first half of 2026, revenue remained relatively flat at $19.4 million compared to $19.4 million in the prior year. The company experienced a net loss of $0.7 million for the quarter, contrasting with a net income of $0.6 million in the previous year. The shift to a net loss was primarily attributed to increased operating expenses, including higher personnel costs and stock-based compensation, which outpaced a modest decline in gross margin.

In terms of operational performance, SANUWAVE's UltraMIST® system revenue fell significantly, down 34% to $2.3 million, while consumables revenue increased by 12% to $7.3 million. The decline in system revenue was driven by a 29% drop in unit volume, reflecting financial pressures in the industry and increased availability of used systems. The company’s gross margin percentage also decreased to 76% from 78% year-over-year, influenced by a shift in revenue mix towards lower-margin consumables.

The company’s total operating expenses for the second quarter rose to $7.7 million, up from $6.4 million in the same quarter of 2025. This increase was largely due to higher general and administrative expenses, which grew by 12% to $4.9 million, and a significant rise in research and development costs, which surged by 224% to $0.6 million. The total net loss for the first half of 2026 was $2.1 million, an improvement from a net loss of $5.6 million in the same period of 2025, primarily due to lower interest expenses following a debt refinancing in September 2025.

As of June 30, 2026, SANUWAVE had cash and cash equivalents of $9.4 million, down from $11.9 million at the end of 2025. The company’s total liabilities decreased to $33.8 million from $35.7 million, reflecting a reduction in secured term loan obligations. The company remains in compliance with its debt covenants and anticipates sufficient resources to meet its working capital needs and capital expenditures for at least the next twelve months. Looking ahead, SANUWAVE plans to continue evaluating opportunities to enhance its capital structure and support its growth strategy, while also addressing identified weaknesses in its internal controls over financial reporting.